Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study

The present study aimed at evaluating whether a weekly cisplatin, epirubicin, and paclitaxel (PET) regimen could increase the pathological complete response (pCR) rate in comparison with a tri-weekly epirubicin and paclitaxel administration in locally advanced breast cancer (LABC) patients. Patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Frasci, G, D'Aiuto, G, Comella, P, Thomas, R, Botti, G, Di Bonito, M, De Rosa, V, Iodice, G, Rubulotta, M R, Comella, G
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2006
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360722/
https://ncbi.nlm.nih.gov/pubmed/17047649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603395
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars